Bremelanotide U.S. label context · version 1
This page preserves this version's wording and source pins. Open the current profile →
What does the U.S. product label say?
Vyleesi · Read September 15, 2026 · Preserved label summary 1
Which population and use does the label cover?
The cited U.S. label covers acquired, generalized hypoactive sexual desire disorder in premenopausal women, with specified exclusions. It does not cover men, postmenopausal women or enhancement of sexual performance. Label: 1 ↗
Which safety limits matter?
The label lists uncontrolled hypertension or known cardiovascular disease as contraindications. It describes transient blood-pressure increases, heart-rate reduction, focal hyperpigmentation and nausea. Label: 1, 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
VYLEESI (bremelanotide) injection · SPL version 1 · published 2025-11-18
Label ZIP SHA-256: deb36c45aeecfb5e78f4b9ff837af0dfa1d12acf404c2d0424a6c279343cc780. Extracted XML SHA-256: 40f565dabb4834a5e8ae91adc6836df37b62102e1b94a57aa2bfc74969fa09be.